Class summary at a glance.

Every drug in the HER2/neu Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $46.3Mcombined across class
Total Rx claims: 10K2K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Trastuzumab-Qyyp

Brand: Trazimera · 5K Part D claims (CY24) · 772 beneficiaries · First FDA approval: 2020-02-24

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $18.3M

Class share

40%

of class CY24 spend

View profile →

Pertuzumab

Brand: PERJETA · 2K Part D claims (CY24) · 438 beneficiaries · First FDA approval: 2012-06-08

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $16.6M

Class share

36%

of class CY24 spend

View profile →

Trastuzumab

Brand: HERZUMA · 1K Part D claims (CY24) · 224 beneficiaries · First FDA approval: 2017-02-10

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $7.2M

Class share

16%

of class CY24 spend

View profile →

Trastuzumab-Anns

Brand: Kanjinti · 514 Part D claims (CY24) · 92 beneficiaries · First FDA approval: 2019-06-11

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $2.3M

Class share

of class CY24 spend

View profile →

Trastuzumab-Dkst

Brand: OGIVRI · 614 Part D claims (CY24) · 117 beneficiaries · First FDA approval: 2023-10-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $1.8M

Class share

of class CY24 spend

View profile →

Margetuximab-Cmkb

Brand: MARGENZA · — Part D claims (CY24) · First FDA approval: 2021-01-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ontruzant

— Part D claims (CY24) · First FDA approval: 2021-06-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.